{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"529"},{"groupId":"OG001","value":"536"},{"groupId":"OG002","value":"539"}]}],"title":"≥ 1 adverse event (AE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"433"},{"groupId":"OG002","value":"480"}]}],"title":"≥ 1 grade (Gr) 3 or 4 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"38"}]}],"title":"≥ 1 grade (Gr) 5 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"308"},{"groupId":"OG002","value":"270"}]}],"title":"≥ 1 serious adverse event (SAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"506"},{"groupId":"OG001","value":"501"},{"groupId":"OG002","value":"527"}]}],"title":"≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"482"},{"groupId":"OG001","value":"481"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 AE related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"429"},{"groupId":"OG001","value":"410"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 AE related to dexamethasone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"441"}]}],"title":"≥ 1 AE related to melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"326"}]}],"title":"≥ 1 AE related to prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"493"}]}],"title":"≥ 1 AE related to thalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"145"}]}],"title":"≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"326"},{"groupId":"OG002","value":"423"}]}],"title":"≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"290"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 grade 3 or 4 AE related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 grade 3 or 4 AE related to dexamethasone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"307"}]}],"title":"≥ 1 grade 3 or 4 AE related to melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"118"}]}],"title":"≥ 1 grade 3 or 4 AE related to prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"316"}]}],"title":"≥ 1 grade 3 or 4 AE related to Thalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"49"}]}],"title":"≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"}]}],"title":"≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 Grade 5 AE related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}]}],"title":"≥ 1 Grade 5 AE related to Dexamethasone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"}]}],"title":"≥ 1 Grade 5 AE related to melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}],"title":"≥ 1 Grade 5 AE related to prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}],"title":"≥ 1 Grade 5 AE related to Thalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"}]}],"title":"≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"142"}]}],"title":"≥1 SAE related to Len/Dex/Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 SAE related to Lenalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 SAE related to dexamethasone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"75"}]}],"title":"≥1 SAE related to melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"62"}]}],"title":"≥1 SAE related to prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"94"}]}],"title":"≥1 SAE related to thalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"27"}]}],"title":"≥1 SAE related to Len/Dex or Mel/Pred/Thal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"153"}]}],"title":"≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to Lenalidomide withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to dexamethasone withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"83"}]}],"title":"≥1 AE leading to melphalan withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"78"}]}],"title":"≥1 AE leading to prednisone withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"146"}]}],"title":"≥1 AE leading to Thalidomide withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"71"}]}],"title":"≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"214"},{"groupId":"OG002","value":"348"}]}],"title":"≥1AE leading to Len/Dex/Mel/Pred/Thal reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to Lenalidomide reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to dexamethasone reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"199"}]}],"title":"≥1 AE leading to melphalan reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"47"}]}],"title":"≥1 AE leading to prednisone reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"254"}]}],"title":"≥1 AE leading to thalidomide reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"2"}]}],"title":"≥1AE leading to Len/Dex or Mel/Pred/Thal reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"321"},{"groupId":"OG002","value":"419"}]}],"title":"≥1 AE leading to Rd or MPT interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"301"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to Lenalidomide interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"0"}]}],"title":"≥1 AE leading to dexamethasone interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"328"}]}],"title":"≥1 AE leading to melphalan interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"324"}]}],"title":"≥1 AE leading to prednisone interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"388"}]}],"title":"≥1 AE leading to Thalidomide interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"241"},{"groupId":"OG002","value":"249"}]}],"title":"≥1 AE leading to Len and Dex or MPT interruption"}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"540"},{"groupId":"OG002","value":"541"}],"units":"Participants"}],"description":"A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.","groups":[{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.","id":"OG000","title":"Lenalidomide and Low-Dose Dexamethasone (Rd)"},{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.","id":"OG001","title":"Lenalidomide and Dexamethasone Rd18"},{"description":"Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.","id":"OG002","title":"Melphalan + Prednisone + Thalidomide (MPT)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at least one dose treatment dose of treatment in any arm","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm","title":"Number of Participants With Adverse Events (AEs) During the Active Treatment Phase","type":"SECONDARY","unitOfMeasure":"Participants"}